Business Wire

CA-BIOCELL-TECHNOLOGY

13.6.2019 02:53:04 CEST | Business Wire | Press release

Share
BioCell Technology Announces BioCell Collagen® Skin Aging Clinical Trial Poster Presentation at ASN Nutrition 2019

BioCell Technology, LLC, a branded dietary ingredient supplier, today announced the presentation of The Effects of Skin Aging Associated with the Use of BioCell Collagen® in Healthy Adult Females: A Randomized, Double-blind, Placebo-controlled Clinical Trial . These results were presented in a poster session at the American Society for Nutrition (ASN) Nutrition 2019 on June 9, 2019, and are available at http://bit.ly/2WzhODi . This poster will be published as part of the proceedings of Nutrition 2019 by ASN. The manuscript of the study will be published in the online and print versions of the peer review journal Alternative Therapies in Health and Medicine (ATHM).

The goal of the study was to determine if a correlation existed between the effects of the dietary supplement, BioCell-Collagen®, with changes associated with skin aging. The study was a 128-female subject, 12-week, double-blind, placebo-controlled trial. Participants were randomly assigned to an intervention or a placebo. The intervention consisted of twice daily 500mg oral administration of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract dietary ingredient composed of a naturally-occurring matrix of collagen type-II peptides (≥300 mg), chondroitin sulfate (≥100 mg), and hyaluronic acid (≥50 mg).

For the 113 participants completing the study, BioCell Collagen® supplementation compared to a placebo resulted in:

  • Significantly reduced facial lines and wrinkles (P = .019) and crow’s feet lines and wrinkles (P = .05)
  • Increased skin elasticity (P = .008) and cutaneous collagen content (P < .001) by 12%
  • Improved indicators associated with a more youthful skin appearance based on visual grading and wrinkle width (P = .046)
  • Decreased skin dryness and erythema.
  • No difference existed between the supplement and the placebo for skin surface water content or retention. The supplement was well tolerated, with no reported adverse reactions.

“We are very excited to publish the findings of our largest study to date, which further supports the efficacy of our flagship dietary ingredient BioCell Collagen®. Human clinical studies continue to be the gold standard for substantiating dietary supplement claims and we take pride that our licensed partners can take advantage,” said Suhail Ishaq, president of BioCell Technology.

The latest study validates an earlier pilot study that demonstrated similar results- Schwartz SR, Park J. Ingestion of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial aging signs. Clin Interven Aging . 2012; 7: 267-273.

“An impressive example of how a series of studies, capped by a randomized, double-blind, placebo-controlled, supports a ‘beauty from within’ claim in healthy women. Even more impressive was that the results remained statistically significant even after an intention-to-treat analysis was performed that included the few subjects that dropped out of the study. Such an analysis is seen in only about 15-20% of randomized, placebo-controlled blinded clinical studies published in leading medical journals,” said Alexander Schauss, PhD, FACN, CFS, Senior Director of Research at AIBMR Life Sciences, and the corresponding author.

“It is important that the supplement industry conducts research at the pinnacle of good science and this includes a double blind, properly populated study like this one,” said Stephen Schwartz, President and CEO of International Research Services, Inc.

About BioCell Collagen ®

BioCell Collagen® is a clinically tested branded dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials, including trials on safety, efficacy, and bioavailability. BioCell Collagen® is self-affirmed GRAS (Generally Recognized As Safe). BioCell Collagen® is non-GMO and free of gluten, soy, shellfish, fish, egg, milk, peanuts and sugar. BioCell Collagen® is made exclusively in the USA and Europe. For more information, visit www.BioCellCollagen.com .

About BioCell Technology, LLC

BioCell Technology is a research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information visit www.BioCellTechnology.com .

Contact:

Suhail Ishaq President of BioCell Technology, LLC 714-632-1231

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Impartner Launches the First CPQ Built for Partners20.8.2026 15:00:00 CEST | Press release

New quote management capability brings configure, price, and quote (CPQ) into Impartner’s PRM platform, connecting product configuration, pricing, segmentation, and approvals. Impartner, the leading partner revenue orchestration platform, today announced the launch ofImpartner CPQ, giving partners a direct path to create and advance quotes within the Impartner PRM platform. The new capability enables faster movement from opportunity to submission while giving vendors control over the rules, products, pricing, and approvals that govern each transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820479441/en/ Give partners a faster path from opportunity to quote with Impartner's CPQ. For many partnership programs, quoting remains a largely manual process. Partners often depend on vendor sales teams to prepare quotes because traditional CPQ systems are designed primarily for direct sellers or require additional licensin

Scientist.com Expands R&D Platform Capabilities with SciSure’s Integrated LabOps Inventory and Compliance Services20.8.2026 14:55:00 CEST | Press release

Strategic integration connects scientific procurement with lab operations, inventory, and EHS compliance Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, today announced an expansion of its platform capabilities through an integration with SciSure’s lab management and EHS compliance tools. The partnership gives biopharma organizations a more unified workflow connecting scientific procurement directly with laboratory operations. “By bringing SciSure’s inventory management, safety, and compliance capabilities into the Scientist.com ecosystem, we are closing the gap between sourcing reagents and safely managing them in the laboratory,” said Jon Zibell, VP of Global Alliances at SciSure. “Together, our platforms connect product information, safety checks, and inventory management, giving research, lab operations, and EHS teams greater visibility from purchase request through disposal.” The integration connects procurement, s

NETFORCE Accelerates Its U.S. Industrial Expansion as a New Intermediate-Force Market Takes Shape20.8.2026 14:23:00 CEST | Press release

Backed by two granted and active U.S. patents, a fully industrialized technology and commercial commitments spanning more than 50 countries, the French company is now seeking leading U.S. industrial and strategic partners to help shape the future of this emerging market. For the first time, major U.S. federal agencies are beginning to structure procurement around a new category of intermediate-force equipment, giving officers an additional option between verbal presence and higher levels of force. NETFORCE believes companies establishing themselves at this early stage will benefit from a significant first-mover advantage as this category expands nationwide. This is precisely the market NETFORCE anticipated years ago, having invested heavily in research, industrialization and international intellectual property well before the category attracted attention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820951658/en/ COPYRI

Cox Capital To Expand Liquidity Solutions for Retail Investors in Private Markets20.8.2026 14:00:00 CEST | Press release

The liquidity solutions provider for alternative investments prepares to launch tender offers for interval funds in the coming months and affirms its ongoing program for non-traded BDCs. Cox Capital Partners, LP (“Cox Capital”), a provider of liquidity solutions for retail holders of illiquid alternative investments, today announced plans to expand its existing tender offer program for non‑traded business development companies (BDCs) into the rapidly growing interval fund market. The move affirms the company’s role as a provider of liquidity solutions across the private markets landscape for the wealth advisory channel. Over the past six years, Cox Capital has built a platform for sourcing and executing secondary liquidity transactions for retail investors in non‑traded BDCs and other illiquid vehicles, working with financial advisors and intermediaries across independent broker‑dealers, RIAs, and major wirehouses. Cox Capital today announced plans to expand that platform to interval f

Esri Expands World Imagery with Airbus High-Resolution Basemap Coverage for 2,000 Cities Worldwide20.8.2026 14:00:00 CEST | Press release

New Airbus Imagery Enhances World Imagery Basemap as Part of Broader Expansion Announced at 2026 Esri User Conference Esri is enhancing its World Imagery basemap through new agreements with Airbus, Vantor, and Nearmap, announced during the 2026 Esri User Conference. Airbus will begin delivering 30 cm basemap imagery for approximately 2,000 cities worldwide starting in the second half of 2026. Airbus basemaps provide highly accurate, color-consistent, nearly cloud-free coverage designed to deliver fresher and more detailed urban imagery. Additional enhancements include expanded metropolitan coverage from Nearmap and continued global basemap updates from Vantor. At the 2026 Esri User Conference (UC), the global leader in location intelligence announced a significant enhancement to its World Imagery basemap through a new agreement with Airbus. The collaboration will enable Esri to provide ArcGIS users with high-resolution imagery coverage for approximately 2,000 cities around the world th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye